Skip to main content

Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Delcath Systems (DCTH) and Certara (CERT)

Tipranks - Tipranks - Tue Feb 24, 9:40AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Henry Schein (HSIC – Research Report), Delcath Systems (DCTH – Research Report) and Certara (CERT – Research Report).

Claim 50% Off TipRanks Premium

Henry Schein (HSIC)

In a report released today, Brandon Vazquez from William Blair maintained a Hold rating on Henry Schein. The company’s shares closed last Monday at $78.98.

According to TipRanks.com, Vazquez is a 2-star analyst with an average return of 1.0% and a 43.0% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Medline, Inc. Class A, and Edwards Lifesciences. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Henry Schein with a $88.80 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Delcath Systems (DCTH)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Delcath Systems today. The company’s shares closed last Monday at $9.85.

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 34.1% and a 59.1% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Diamedica Therapeutics, and Fennec Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Delcath Systems with a $24.20 average price target, implying a 149.0% upside from current levels. In a report issued on February 18, BTIG also maintained a Buy rating on the stock with a $23.00 price target.

Certara (CERT)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Certara today. The company’s shares closed last Monday at $6.38.

According to TipRanks.com, Hewitt has 0 stars on 0-5 stars ranking scale with an average return of -6.8% and a 36.3% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Park Dental Partners, Inc., and Dyadic International. ;'>

Currently, the analyst consensus on Certara is a Moderate Buy with an average price target of $12.40.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).